Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2018

01.04.2018 | Research Article

Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology

verfasst von: Guillaume Hébert, Florence Netzer, Sylvain Landry Kouakou, François Lemare, Etienne Minvielle, the IATRIGGER Working Group

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most appropriate. Although a generic tool exists, its use for ADEs in oncology has not been convincing. The development of a focused version is therefore necessary. Objective To provide an oncology-focused trigger tool that evaluates the prevalence, harm, and preventability in a standardised method for pragmatic use in ADE surveillance. Setting Hospitals with cancer care in France. Method The tool has been constructed in two steps: (1) constitution of an oncology-centred list of ADEs; 30 pharmacists/practitioners in cancer care from nine hospitals selected a list of ADEs using a method of agreement adapted from the RAND/UCLA Appropriateness Method; and (2) construction of three standardised dimensions for the characterisation of each ADE (including causality, severity, and preventability). Main outcome measure The main outcome measure was validation of the tool, including preventability criteria. Results The tool is composed of a final list of 15 ADEs. For each ADE, a ‘reviewer form’ has been designed and validated by the panel. It comprises (1) the trigger(s), (2) flowcharts to guide the reviewer, (3) criteria for grading harm, and (4) a standardised assessment of preventability with 6–14 closed sentences for each ADE in terms of therapeutic management and/or prevention of side-effects. Conclusion A complete ‘ready-to-use’ tool for ADE monitoring in oncology has been developed that allows the assessment of three standardised dimensions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324:370–6.CrossRefPubMed Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324:370–6.CrossRefPubMed
3.
Zurück zum Zitat Bates DW, Leape LL, Carruthers SG. Melmon and Morrelli’s clinical pharmacology: basic principles in therapeutics. New York: McGraw-Hill; 2000. Bates DW, Leape LL, Carruthers SG. Melmon and Morrelli’s clinical pharmacology: basic principles in therapeutics. New York: McGraw-Hill; 2000.
4.
Zurück zum Zitat Lipczak H, Neckelmann K, Steding-Jessen M, Jakobsen E, Knudsen JL. Uncertain added value of Global Trigger Tool for monitoring of patient safety in cancer care. Dan Med Bull. 2011;58:A4337.PubMed Lipczak H, Neckelmann K, Steding-Jessen M, Jakobsen E, Knudsen JL. Uncertain added value of Global Trigger Tool for monitoring of patient safety in cancer care. Dan Med Bull. 2011;58:A4337.PubMed
5.
Zurück zum Zitat Lipczak H, Knudsen JL, Nissen A. Safety hazards in cancer care: findings using three different methods. BMJ Qual Saf. 2011;20:1052–6.CrossRefPubMed Lipczak H, Knudsen JL, Nissen A. Safety hazards in cancer care: findings using three different methods. BMJ Qual Saf. 2011;20:1052–6.CrossRefPubMed
6.
Zurück zum Zitat Nazer LH, Hawari F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27:208–13.CrossRefPubMed Nazer LH, Hawari F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27:208–13.CrossRefPubMed
7.
Zurück zum Zitat Jha AK, Kuperman GJ, Teich JM, Leape LL, Shea B, Rittenberg E, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998;5:305–14.CrossRefPubMedPubMedCentral Jha AK, Kuperman GJ, Teich JM, Leape LL, Shea B, Rittenberg E, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998;5:305–14.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc. 2006;13:372–7.CrossRefPubMedPubMedCentral Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc. 2006;13:372–7.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Wong BM, Dyal S, Etchells EE, Knowles S, Gerard L, Diamantouros A, et al. Application of a trigger tool in near real time to inform quality improvement activities: a prospective study in a general medicine ward. BMJ Qual Saf. 2015;24:272–81.CrossRefPubMedPubMedCentral Wong BM, Dyal S, Etchells EE, Knowles S, Gerard L, Diamantouros A, et al. Application of a trigger tool in near real time to inform quality improvement activities: a prospective study in a general medicine ward. BMJ Qual Saf. 2015;24:272–81.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280:1000–5.CrossRefPubMed Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280:1000–5.CrossRefPubMed
11.
Zurück zum Zitat Michel P, Quenon JL, de Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ. 2004;328:199.CrossRefPubMedPubMedCentral Michel P, Quenon JL, de Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ. 2004;328:199.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Griffin FA, Resar RK. IHI Global Trigger Tool for measuring adverse events. 2nd ed. Cambridge: Institute for Healthcare Improvement; 2009. Griffin FA, Resar RK. IHI Global Trigger Tool for measuring adverse events. 2nd ed. Cambridge: Institute for Healthcare Improvement; 2009.
13.
Zurück zum Zitat Classen DC, Resar RK, Griffin FA, Federico F, Frankel T, Kimmel N, et al. ‘Global trigger tool’ shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff (Millwood). 2011;30:581–9.CrossRef Classen DC, Resar RK, Griffin FA, Federico F, Frankel T, Kimmel N, et al. ‘Global trigger tool’ shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff (Millwood). 2011;30:581–9.CrossRef
14.
Zurück zum Zitat Härkänen M, Kervinen M, Ahonen J, Voutilainen A, Turunen H, Vehviläinen-Julkunen K. Patient-specific risk factors of adverse drug events in adult inpatients – evidence detected using the Global Trigger Tool method. J Clin Nurs. 2015;24:582–91.CrossRefPubMed Härkänen M, Kervinen M, Ahonen J, Voutilainen A, Turunen H, Vehviläinen-Julkunen K. Patient-specific risk factors of adverse drug events in adult inpatients – evidence detected using the Global Trigger Tool method. J Clin Nurs. 2015;24:582–91.CrossRefPubMed
15.
Zurück zum Zitat Sharek PJ. The Emergence of the Trigger Tool as the Premier Measurement Strategy for Patient Safety. AHRQ WebM&M. 2012;2012:1–5. Sharek PJ. The Emergence of the Trigger Tool as the Premier Measurement Strategy for Patient Safety. AHRQ WebM&M. 2012;2012:1–5.
16.
Zurück zum Zitat Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics. 2008;121:e927–35.CrossRefPubMed Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics. 2008;121:e927–35.CrossRefPubMed
17.
Zurück zum Zitat Sharek PJ, Horbar JD, Mason W, Bisarya H, Thurm CW, Suresh G, et al. Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics. 2006;118:1332–40.CrossRefPubMed Sharek PJ, Horbar JD, Mason W, Bisarya H, Thurm CW, Suresh G, et al. Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics. 2006;118:1332–40.CrossRefPubMed
18.
Zurück zum Zitat Mull HJ, Rosen AK, Shimada SL, Rivard PE, Nordberg B, Long B, et al. Assessing the potential adoption and usefulness of concurrent, action-oriented, electronic adverse drug event triggers designed for the outpatient setting. EGEMS (Washington, DC). 2015;3:1116. Mull HJ, Rosen AK, Shimada SL, Rivard PE, Nordberg B, Long B, et al. Assessing the potential adoption and usefulness of concurrent, action-oriented, electronic adverse drug event triggers designed for the outpatient setting. EGEMS (Washington, DC). 2015;3:1116.
19.
Zurück zum Zitat Rosen AK, Mull HJ, Kaafarani HMA, Nebeker JR, Shimada S, Helwig A, et al. Applying trigger tools to detect adverse events associated with outpatient surgery. J Patient Saf. 2011;7:45–59.CrossRefPubMed Rosen AK, Mull HJ, Kaafarani HMA, Nebeker JR, Shimada S, Helwig A, et al. Applying trigger tools to detect adverse events associated with outpatient surgery. J Patient Saf. 2011;7:45–59.CrossRefPubMed
20.
Zurück zum Zitat Klopotowska JE, Wierenga PC, Stuijt CCM, Arisz L, Dijkgraaf MGW, Kuks PFM, et al. Adverse drug events in older hospitalized patients: results and reliability of a comprehensive and structured identification strategy. PLoS ONE. 2013;8:e71045.CrossRefPubMedPubMedCentral Klopotowska JE, Wierenga PC, Stuijt CCM, Arisz L, Dijkgraaf MGW, Kuks PFM, et al. Adverse drug events in older hospitalized patients: results and reliability of a comprehensive and structured identification strategy. PLoS ONE. 2013;8:e71045.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Carnevali L, Krug B, Amant F, Van Pee D, Gérard V, de Béthune X, et al. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital. Ann Pharmacother. 2013;47:1414–9.CrossRefPubMed Carnevali L, Krug B, Amant F, Van Pee D, Gérard V, de Béthune X, et al. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital. Ann Pharmacother. 2013;47:1414–9.CrossRefPubMed
22.
Zurück zum Zitat Franklin BD, Birch S, Schachter M, Barber N. Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm Pract. 2010;18:305–11.CrossRefPubMed Franklin BD, Birch S, Schachter M, Barber N. Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm Pract. 2010;18:305–11.CrossRefPubMed
23.
Zurück zum Zitat Kalenderian E, Walji MF, Tavares A, Ramoni RB. An adverse event trigger tool in dentistry: a new methodology for measuring harm in the dental office. J Am Dent Assoc. 2013;144:808–14.CrossRefPubMed Kalenderian E, Walji MF, Tavares A, Ramoni RB. An adverse event trigger tool in dentistry: a new methodology for measuring harm in the dental office. J Am Dent Assoc. 2013;144:808–14.CrossRefPubMed
24.
Zurück zum Zitat Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35:105–26.CrossRefPubMed Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35:105–26.CrossRefPubMed
25.
Zurück zum Zitat Mattsson TO, Knudsen JL, Lauritsen J, Brixen K, Herrstedt J. Assessment of the global trigger tool to measure, monitor and evaluate patient safety in cancer patients: reliability concerns are raised. BMJ Qual Saf. 2013;22:571–9.CrossRefPubMed Mattsson TO, Knudsen JL, Lauritsen J, Brixen K, Herrstedt J. Assessment of the global trigger tool to measure, monitor and evaluate patient safety in cancer patients: reliability concerns are raised. BMJ Qual Saf. 2013;22:571–9.CrossRefPubMed
26.
Zurück zum Zitat Hébert G, Netzer F, Ferrua M, Ducreux M, Lemare F, Minvielle E. Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool. Eur J Cancer. 2015;51:427–35.CrossRefPubMed Hébert G, Netzer F, Ferrua M, Ducreux M, Lemare F, Minvielle E. Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool. Eur J Cancer. 2015;51:427–35.CrossRefPubMed
27.
Zurück zum Zitat Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm. 2002;59:1742–9.PubMed Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm. 2002;59:1742–9.PubMed
28.
Zurück zum Zitat Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P. The RAND/UCLA appropriateness method user’s manual. California: Santa Monica; 2001. Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P. The RAND/UCLA appropriateness method user’s manual. California: Santa Monica; 2001.
30.
Zurück zum Zitat Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111–8.PubMed Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111–8.PubMed
31.
Zurück zum Zitat Dangoumau J, Evreux JC, Jouglard J. Method for determination of undesirable effects of drugs. Therapie. 1978;33:373–81.PubMed Dangoumau J, Evreux JC, Jouglard J. Method for determination of undesirable effects of drugs. Therapie. 1978;33:373–81.PubMed
32.
Zurück zum Zitat Kaafarani HMA, Rosen AK, Nebeker JR, Shimada S, Mull HJ, Rivard PE, et al. Development of trigger tools for surveillance of adverse events in ambulatory surgery. Qual Saf Health Care. 2010;19:425–9.PubMed Kaafarani HMA, Rosen AK, Nebeker JR, Shimada S, Mull HJ, Rivard PE, et al. Development of trigger tools for surveillance of adverse events in ambulatory surgery. Qual Saf Health Care. 2010;19:425–9.PubMed
33.
Zurück zum Zitat Bourrée F, Michel P, Salmi LR. Méthodes de consensus: revue des méthodes originales et de leurs grandes variantes utilisées en santé publique. Rev Epidemiol Sante Publique. 2008;56:415–23.CrossRefPubMedPubMedCentral Bourrée F, Michel P, Salmi LR. Méthodes de consensus: revue des méthodes originales et de leurs grandes variantes utilisées en santé publique. Rev Epidemiol Sante Publique. 2008;56:415–23.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Grenier-Sennelier C, Corriol C, Daucourt V, Michel P, Minvielle E. Développement d’indicateurs de qualité au sein des établissements de santé: le projet COMPAQH. Rev Epidemiol Sante Publique. 2005;53:22–30.CrossRef Grenier-Sennelier C, Corriol C, Daucourt V, Michel P, Minvielle E. Développement d’indicateurs de qualité au sein des établissements de santé: le projet COMPAQH. Rev Epidemiol Sante Publique. 2005;53:22–30.CrossRef
35.
Zurück zum Zitat Handler SM, Hanlon JT, Perera S, Roumani YF, Nace DA, Fridsma DB, et al. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J Am Geriatr Soc. 2008;56:808–15.CrossRefPubMedPubMedCentral Handler SM, Hanlon JT, Perera S, Roumani YF, Nace DA, Fridsma DB, et al. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J Am Geriatr Soc. 2008;56:808–15.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Mull HJ, Nebeker JR, Shimada SL, Kaafarani HMA, Rivard PE, Rosen AK. Consensus building for development of outpatient adverse drug event triggers. J Patient Saf. 2011;7:66–71.CrossRefPubMedPubMedCentral Mull HJ, Nebeker JR, Shimada SL, Kaafarani HMA, Rivard PE, Rosen AK. Consensus building for development of outpatient adverse drug event triggers. J Patient Saf. 2011;7:66–71.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Unbeck M, Lindemalm S, Nydert P, Ygge B-M, Nylén U, Berglund C, et al. Validation of triggers and development of a pediatric trigger tool to identify adverse events. BMC Health Serv Res. 2014;14:655.CrossRefPubMedPubMedCentral Unbeck M, Lindemalm S, Nydert P, Ygge B-M, Nylén U, Berglund C, et al. Validation of triggers and development of a pediatric trigger tool to identify adverse events. BMC Health Serv Res. 2014;14:655.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat de Wet C, Bowie P. The preliminary development and testing of a global trigger tool to detect error and patient harm in primary-care records. Postgrad Med J. 2009;85:176–80.CrossRefPubMed de Wet C, Bowie P. The preliminary development and testing of a global trigger tool to detect error and patient harm in primary-care records. Postgrad Med J. 2009;85:176–80.CrossRefPubMed
40.
Zurück zum Zitat Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377–84.CrossRefPubMed Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377–84.CrossRefPubMed
41.
Zurück zum Zitat Olivier P, Caron J, Haramburu F, Imbs J-L, Jonville-Béra A-P, Lagier G, et al. Validation d’une échelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Therapie. 2005;60:39–45.CrossRefPubMed Olivier P, Caron J, Haramburu F, Imbs J-L, Jonville-Béra A-P, Lagier G, et al. Validation d’une échelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Therapie. 2005;60:39–45.CrossRefPubMed
42.
Zurück zum Zitat Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA. 2013;309:139–40.CrossRefPubMed Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA. 2013;309:139–40.CrossRefPubMed
43.
Zurück zum Zitat Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMed Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMed
44.
Zurück zum Zitat de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.CrossRefPubMed de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.CrossRefPubMed
45.
Zurück zum Zitat Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMed Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMed
46.
Zurück zum Zitat Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. Outpatient adverse drug events identified by screening electronic health records. J Patient Saf. 2010;6:91–6.CrossRefPubMed Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. Outpatient adverse drug events identified by screening electronic health records. J Patient Saf. 2010;6:91–6.CrossRefPubMed
47.
Zurück zum Zitat Jha AK, Laguette J, Seger AC, Bates DW. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc. 2008;15:647–53.CrossRefPubMedPubMedCentral Jha AK, Laguette J, Seger AC, Bates DW. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc. 2008;15:647–53.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Classen DC, Burke JP, Pestotnik SL, Evans RS, Stevens LE. Surveillance for quality assessment: IV. Surveillance using a hospital information system. Infect Control Hosp Epidemiol. 1991;12:239–44.CrossRefPubMed Classen DC, Burke JP, Pestotnik SL, Evans RS, Stevens LE. Surveillance for quality assessment: IV. Surveillance using a hospital information system. Infect Control Hosp Epidemiol. 1991;12:239–44.CrossRefPubMed
Metadaten
Titel
Development of a ‘ready-to-use’ tool that includes preventability, for the assessment of adverse drug events in oncology
verfasst von
Guillaume Hébert
Florence Netzer
Sylvain Landry Kouakou
François Lemare
Etienne Minvielle
the IATRIGGER Working Group
Publikationsdatum
01.04.2018
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2018
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0542-3

Weitere Artikel der Ausgabe 2/2018

International Journal of Clinical Pharmacy 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.